Mollugin - CAS 55481-88-4

Mollugin (Rubimaillin) may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.

ROS, Reactive Oxygen Species, c-Myc, NF-κB, Apoptosis, VEGFR, HER, JAK

Tyrosine Kinase/Adaptors, Angiogenesis, Metabolism, Immunology/Inflammation, NF-κB, JAK/STAT signaling, Cell Cycle/Checkpoint, Apoptosis, Chromatin/Epigenetic, Stem Cells

55389

0.9987

C17H16O4

284.31

COC(=O)c1c(O)c2ccccc2c2OC(C)(C)C=Cc12

-20°C

Ice Packs

Natural Product